Washington, USA
08048034998
+919359902383
ANTI CANCER MEDICINE

GEMLIEVA 1000 MG Injection (Gemcitabine) Bulk Exporter — Ernest Oncology | Buy Online USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, Asia

In stockcod not available
Phone Number

08048034998

Please keep 0 before dialling the number.

Mon-Thu: 10 AM - 2 PM • Fri: 3 PM - 7AM

Other Website Visit our other website
Address Washington , District of Columbia , District of Columbia

Washington, USA, United States, 1

Description

GEMLIEVA 1000 MG Injection (Gemcitabine): High-Capacity Nucleoside Analog for Comprehensive Oncology GEMLIEVA 1000 MG Injection is a high-dose antineoplastic medication featuring the active pharmaceutical ingredient Gemcitabine. Classified as a pyrimidine nucleoside analog (antimetabolite), it is a vital component in the systemic treatment of several aggressive solid tumors. Manufactured under strict GMP guidelines, GEMLIEVA 1000 MG is designed to deliver a high concentration of the active agent, facilitating clinical efficiency for high-volume oncology centers across the USA, UK, Europe, UAE, and Asia. Therapeutic Indications and Global Clinical Usage Advanced Pancreatic Cancer: Indicated as the standard first-line treatment for patients with locally advanced or metastatic adenocarcinoma of the pancreas. Non-Small Cell Lung Cancer (NSCLC): Used in combination with cisplatin for the treatment of patients with inoperable, locally advanced, or metastatic NSCLC. Metastatic Breast Cancer: Employed in combination with paclitaxel for patients who have relapsed following prior anthracycline-containing adjuvant chemotherapy. Advanced Ovarian Cancer: Used in combination with carboplatin for patients with relapsed disease following platinum-based first-line therapy. Bladder Cancer: Frequently utilized in combination with cisplatin for advanced or metastatic transitional cell carcinoma. Mechanism of Action: How GEMLIEVA 1000 MG Works Metabolic Activation: Once infused, Gemcitabine is converted intracellularly into active metabolites: gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP). Ribonucleotide Reductase Inhibition: dFdCDP inhibits the enzyme responsible for producing the building blocks of DNA, effectively starving the cancer cell of necessary resources. Masked DNA Chain Termination: dFdCTP competes with natural building blocks for incorporation into the DNA strand. Once incorporated, only one additional nucleotide can be added, which “masks“ the drug from the cell’s repair mechanisms. Self-Potentiation: The reduction in natural building blocks (dCTP) further enhances the incorporation of the drug into DNA. Apoptosis: The irreversible structural damage to the DNA triggers programmed cell death (apoptosis), halting tumor growth. Professional Administration and Safety Protocols Route: Administered strictly via Intravenous (IV) Infusion.Infusion Duration: Typically administered over 30 minutes. Note: Extending infusion time beyond 60 minutes is associated with increased toxicity and should be avoided.Reconstitution: Usually reconstituted with 0.9% Sodium Chloride Injection to reach a final concentration suitable for infusion. Clinical Environment: This high-strength injection must be administered by trained oncology professionals in a setting equipped for continuous monitoring. Safety Profile and Clinical Monitoring Hematological Vigilance: Regular Complete Blood Counts (CBC) are mandatory to monitor for bone marrow suppression (neutropenia, thrombocytopenia, and anemia). Hepatic and Renal Function: Periodic liver function tests (LFTs) and kidney function tests (KFTs) are required, as gemcitabine can cause transient elevations in liver enzymes. Pulmonary Monitoring: Vigilance for rare but serious pulmonary toxicities, such as interstitial pneumonitis or pulmonary edema. Flu-like Symptoms: Monitoring for common side effects like fever, rash, and fatigue, which often occur within 24 hours of infusion. Storage and Global Handling Instructions Storage: Store the unreconstituted vial at controlled room temperature (20°C to 25°C). Protection: Keep the vial in the original packaging to protect from light. Cytotoxic Handling: As a hazardous antineoplastic agent, GEMLIEVA 1000 MG must be prepared and handled using appropriate Personal Protective Equipment (PPE) and disposed of according to international biohazard protocols. Why Choose Ernest Oncology? 100% Genuine Medication: We source directly from GMP-certified channels, ensuring product authenticity and optimal shelf life. Logistics Precision: Our team utilizes secure, pharmaceutical-grade packaging and efficient transit routes to maintain product stability during international transit. Regulatory & Documentation Support: We handle all necessary paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals, clinics, and government health departments worldwide. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestimpex.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

Keywords

Other Products

view all

68179d65be22ee500d53ff54 Card 2

product image
ANTI CANCER MEDICINE

The Comprehensive Guide to Temalieva 250 mg Capsules In precision neuro-oncology and general cancer care, Temalieva 250 mg capsules (containing the active ingredient Temozolomide) stand as a critical therapeutic agent for treating aggressive brain tumors. As a premier pharmaceutical exporter from India, Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) ensures that this life-saving medication is accessible to hospitals, pharmacies, and healthcare systems in London, the UK, the USA, Australia, and South Africa with full regulatory compliance. Product SpecificationsFeatureDetailBrand NameTemalieva 250 (Temozolomide Capsules IP)Strength250 mgDosage FormOral Hard Gelatin CapsulePrimary IndicationGlioblastoma multiforme & anaplastic astrocytomaStorageStore below 25°C in a cool, dry place. Protect from moisture and light. Mechanism of Action: How It Works DNA Alkylation: Once ingested, Temozolomide readily crosses the blood-brain barrier. At physiological pH, it is converted into the active compound MTIC. Interfering with Replication: MTIC methylates DNA at specific locations, which causes DNA strand breaks and cross-linking. This process inhibits the multiplication and growth of rapidly dividing cancer cells, ultimately leading to programmed cell death (apoptosis). Therapeutic Indications & Administration Glioblastoma Multiforme (GBM): Used for newly diagnosed GBM patients in combination with focal radiation therapy, followed by maintenance therapy. Refractory Anaplastic Astrocytoma: Treatment for patients experiencing tumor recurrence or progression after standard therapy. Administration Guidelines Dosing Schedule: Dosing is calculated based on the patient's body surface area (BSA). Ingestion: Swallow the capsules whole with a full glass of water. Do not open, crush, or chew the capsule contents to prevent exposure to the active drug. Minimizing Side Effects: To reduce the incidence of nausea and vomiting, patients are often advised to take the medication on an empty stomach or at bedtime. Clinical Side Effects & Safety Profile Common Side Effects: Nausea, vomiting, headache, fatigue, constipation, and loss of appetite. Prophylactic antiemetics are frequently prescribed. Myelosuppression: The most serious clinical risk is a decrease in bone marrow function, which leads to reduced white blood cell and platelet counts. This increases susceptibility to infections and bruising or bleeding. Liver Function: Patients should undergo regular liver function tests (LFTs) due to the potential for hepatotoxicity. Contraindications: It is contraindicated during pregnancy and breastfeeding due to the risk of fetal harm. Male patients must use effective contraception during treatment and for at least 3 months afterward. Why Source from Ernest Oncology? United Kingdom (London): Providing high-quality, cost-effective generic alternatives for private and public healthcare systems. USA: Delivering bulk quantities that comply with international documentation and safety standards. Australia: Facilitating secure access through compliant supply channels such as the “Special Access Scheme“ (SAS). South Africa: Bridging critical gaps in the oncology market with affordable, high-tier pharmaceutical exports from India. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 📦 Business Type: Exporter | Bulk Supplier | Distributor 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestvision.com www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

68179d65be22ee500d53ff54 Card 2

product image
ANTI CANCER MEDICINE

Comprehensive Product Authority Guide: Temalieva 20mg (Temozolomide) Temalieva 20mg, formulated with the active pharmaceutical ingredient Temozolomide, is a potent oral alkylating antineoplastic agent. It is widely recognized and utilized in neuro-oncology for the treatment of aggressive forms of brain tumors. 1. Advanced Mechanism of Action DNA Methylation: MTIC works by methylating DNA at the O6 and N7 positions of guanine. Cell Cycle Arrest: This methylation damages the genetic material of cancer cells, leading to DNA double-strand breaks and inducing apoptosis (programmed cell death) in rapidly dividing tumor cells. Blood-Brain Barrier Penetration: Because it is highly lipophilic, it crosses the blood-brain barrier easily, making it uniquely effective against primary and secondary brain malignancies. 2. Therapeutic Indications Glioblastoma Multiforme (GBM): Administered in combination with focal radiotherapy as an initial treatment, followed by maintenance therapy to prevent recurrence. Anaplastic Astrocytoma: Prescribed for patients with refractory or progressive malignant glioma, including anaplastic astrocytoma. Other Malignancies: Clinical evaluation has shown efficacy in certain systemic cancers and targeted neuro-oncology protocols. 3. Dosage and Administration Strength: Available as 20mg oral capsules. Administration Protocol: To minimize nausea and ensure consistent bioavailability, the medication should be taken consistently (either always on an empty stomach or always with a light meal) at the same time each day. Handling Instructions: Capsules must be swallowed whole with a full glass of water. They should not be opened, chewed, crushed, or split, as the contents are highly cytotoxic. 4. Safety Profile and Side Effect Management Common Side Effects: Nausea, vomiting, fatigue, headache, and constipation. Hematological Effects: Myelosuppression (reduced red/white blood cell and platelet counts), which increases the risk of serious infections. Monitoring: Frequent complete blood counts (CBC) and liver function tests are recommended throughout the treatment cycle. Why Source from Ernest Oncology? Ernest Oncology—a specialized division of Ernest Pharmaceutical Pvt. Ltd.—is a trusted global exporter, bulk supplier, and distributor. We facilitate the secure, temperature-controlled delivery of life-saving specialty pharmaceuticals worldwide, bridging the gap between state-of-the-art manufacturing in India and the requirements of global healthcare networks. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 📦 Business Type: Exporter | Bulk Supplier | Distributor 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestvision.com www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

68179d65be22ee500d53ff54 Card 2

product image
ANTI CANCER MEDICINE

The Comprehensive Guide to Leuprolide 22.5 mg Injection For healthcare providers, clinics, and pharmaceutical distributors globally, Leuprolide 22.5 mg Injection is a critical, long-acting medication used to manage advanced hormone-dependent conditions. As a leading pharmaceutical exporter and bulk supplier from India, Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) ensures that this vital medication reaches medical facilities across London, New York, Sydney, Johannesburg, and the broader global market with full regulatory compliance. Product Specifications Brand Name: Ernest-Oncology (Leuprolide Acetate) Strength: 22.5 mg Dosage Form: Depot Suspension for Injection (Subcutaneous or Intramuscular) Primary Indication: Advanced prostate cancer, endometriosis, and uterine fibroids. Storage: Store at room temperature (20°C to 25°C), protect from light and moisture. Mechanism of Action: How It Works Initial Stimulation: Upon initial administration, it briefly increases the levels of certain hormones (like testosterone in men and estrogen in women). Down-Regulation: With continuous administration, it desensitizes the pituitary gland. This stops the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Hormone Suppression: Consequently, it drastically reduces the levels of testosterone or estrogen in the body, which effectively slows or stops the growth of hormone-dependent tumors and tissues. Therapeutic Indications & Administration Advanced Prostate Cancer: Palliative treatment to reduce testosterone levels and suppress tumor progression. Endometriosis & Uterine Fibroids: Relieving pelvic pain and shrinking tissue growths in female patients. Administration: * Route: Administered as a subcutaneous or intramuscular injection by a qualified healthcare professional. Frequency: Given once every 3 months due to the extended-release depot delivery system. Clinical Side Effects & Safety Profile Hormone-Suppression Effects: Hot flashes, night sweats, fatigue, mood changes, and decreased sex drive. Bone Mineral Density Loss: Long-term use can lower bone density, carrying a risk of osteoporosis or bone fractures. Initial Tumor Flare: In the first few weeks, prostate cancer symptoms (like bone or nerve pain) may temporarily worsen before improving. Serious Warnings: Rare risks include cardiovascular events (heart attack, stroke), QT prolongation, and severe skin reactions like Stevens-Johnson syndrome. Contraindications: Contraindicated during pregnancy and breastfeeding due to the high risk of fetal harm. Why Source from Ernest Oncology? United Kingdom (London): Supplying cost-effective, high-quality oncology solutions for specialized clinics and hospitals. USA: Delivering bulk quantities that meet international safety, regulatory, and documentation standards. Australia: Ensuring stable access through established supply chains. South Africa: Bridging critical gaps in the oncology market with reliable, top-tier pharmaceutical exports from India. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 📦 Business Type: Exporter | Bulk Supplier | Distributor 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestvision.com www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383